|1.||Markowitz, Lauri E: 13 articles (09/2015 - 08/2011)|
|2.||Wu, T-C: 12 articles (07/2015 - 01/2003)|
|3.||Bosch, F Xavier: 12 articles (10/2014 - 08/2004)|
|4.||Schiller, John T: 11 articles (09/2014 - 04/2004)|
|5.||Franco, Eduardo L: 11 articles (07/2014 - 03/2006)|
|6.||de Sanjosé, Silvia: 10 articles (09/2015 - 08/2006)|
|7.||Castellsagué, Xavier: 10 articles (05/2015 - 08/2004)|
|8.||Garland, Suzanne M: 10 articles (12/2014 - 01/2007)|
|9.||Roden, Richard B S: 9 articles (02/2015 - 08/2004)|
|10.||Alemany, Laia: 8 articles (09/2015 - 07/2013)|
01/01/2015 - "HPV causes 530,000 cervical cancer cases worldwide, which is the second most common cause of cancer deaths in women; a worldwide collaboration among epidemiologists, molecular biologists, vaccinologists, virologists, and clinicians helped lead to the development of two highly effective prophylactive HPV vaccines. "
05/01/2014 - "However, because most cervical cancers are caused by HPV-16/18, it is unlikely that the nonavalent would be used if its efficacy against these types is lower than current HPV vaccines. "
03/01/2014 - "Obstetrician-gynecologists should advise patients and parents that HPV vaccines are most effective in preventing genital cancers when administered before the onset of sexual activity. "
02/26/2014 - "The highly efficacious human papillomavirus (HPV) vaccines contain virus-like particles (VLP) representing genotypes HPV16 and HPV18, which together account for approximately 70% of cervical cancer cases. "
07/01/2012 - "The two currently licensed human papillomavirus (HPV) vaccines are highly efficacious in preventing cervical pre-cancers related to HPV 6, 11, 16 and 18. "
01/01/2011 - "Prophylactic HPV vaccines are safe, well tolerated, and highly efficacious in preventing persistent infections and cervical diseases associated with vaccine-HPV types among young females. "
05/01/2015 - "Although available human papillomavirus (HPV) vaccines have high efficacy against incident infection and disease caused by HPV types that they specifically target, new vaccine trials continue to be needed. "
02/12/2007 - "Phase III trials have demonstrated the efficacy of human papillomavirus (HPV) vaccines in preventing transient and persistent high-risk (hr) HPV infection and precancerous lesions. "
12/01/2013 - "Despite the preliminary nature of this pilot study, the lower prevalence of some HR HPVs (HPV18) and the higher prevalence of other HR HPVs (HPVs 51, 52 and 31) may imply the necessity for the development of more targeted anti-HPV vaccines or other strategies for more efficient protection against oncogenic HPV infection in women from our region."
01/01/2009 - "The included studies show that both available HPV vaccines are effective in preventing HPV 16 and HPV 18 infections and probable resulting premalignant lesions of the cervix. "
|3.||Condylomata Acuminata (Genital Wart)
07/01/2012 - "The aim of this study was to determine the cervical genotype profile of females who presented to an STI Clinic with external genital warts (EGW); and to determine the potential vaccine coverage prior to the uptake of the HPV vaccines. "
09/01/2015 - "HPV vaccines have had dramatic impacts on the prevalence of targeted HPV types (6,11,16 and 18), genital warts and precancerous cervical lesions. "
07/11/2013 - "Prophylactic HPV vaccines target young adolescents to prevent related cervical lesions and even genital warts prior to onset of sexual activity. "
08/01/2009 - "Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom."
06/01/2008 - "One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV types 16 and 18. "
10/01/2014 - "Licensed human papillomavirus (HPV) vaccines provide near complete protection against the types of HPV that most commonly cause anogenital and oropharyngeal cancers (HPV 16 and 18) when administered to individuals naive to these types. "
07/01/2014 - "However, HPV vaccines are presently not recommended for preventing oropharyngeal cancer (OPC), although they have been shown to be highly effective against the HPV strains that are most commonly found in the oropharynx. "
11/12/2013 - "However, HPV vaccines are presently not recommended for preventing oropharyngeal cancer, although they have been shown to be highly effective against the HPV strains that are most commonly found in the oropharynx. "
07/01/2012 - "If proven efficacious, currently available prophylactic HPV vaccines hold great promise for primary prevention of HPV-associated oropharyngeal cancers."
08/01/2011 - "Dental health care personnel (DHCP) should be knowledgeable about the role of HPV in carcinogenesis, the association of HPV with oropharyngeal cancers and HPV vaccines, and they should be prompt in referring patients with suggestive symptoms for evaluation. "
|5.||Cervical Intraepithelial Neoplasia
10/01/2000 - "cervical intraepithelial neoplasia grade III, CINIII) is important, to avoid early contamination of the target population by opportunistic use of licensed HPV vaccines. "
08/01/2006 - "Two virus-like particle human papillomavirus (HPV) vaccines have been shown to be nearly 100% effective in preventing type-specific persistent HPV infections and associated type-specific high-grade cervical intraepithelial neoplasia (CIN). "
01/01/2015 - "The overall objective of this study was to assess the potential impact of current HPV vaccines in preventing cervical cancer in Zambia, by determining the combined prevalence of HPV-16 and/or HPV-18 in invasive cervical cancer (ICC) and high-grade pre-cancer [cervical intraepithelial neoplasia 2 or 3 (CIN2/3)] cases. "
08/01/2009 - "The introduction of HPV vaccines can also prevent other HPV-related sequelae, most importantly cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3), which precede the development of cervical cancer and require clinical follow-up and treatment. "
01/01/2012 - "Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. "
|2.||type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil)
|3.||18 L1 type 16 human papillomavirus vaccine (Cervarix)
|4.||Biological Markers (Surrogate Marker)
|5.||Capsid Proteins (Capsid Protein)
|6.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|7.||DNA (Deoxyribonucleic Acid)
|9.||Oncogene Proteins (Oncogene Protein)
|2.||Cryotherapy (Therapy, Cold)
|4.||Palliative Care (Palliative Medicine)